Product: ITGAM Antibody
Catalog: DF2911
Description: Rabbit polyclonal antibody to ITGAM
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 170 kDa; 127kD(Calculated).
Uniprot: P11215
RRID: AB_2840900

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(88%), Horse(86%), Sheep(88%), Rabbit(88%), Dog(88%)
Clonality:
Polyclonal
Specificity:
ITGAM Antibody detects endogenous levels of total ITGAM.
RRID:
AB_2840900
Cite Format: Affinity Biosciences Cat# DF2911, RRID:AB_2840900.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

antigen CD11b (p170); Antigen CD11b p170; CD11 antigen like family member B; CD11 antigen-like family member B; CD11b; CD11b/CD18; CD49d; Cell surface glycoprotein MAC-1 subunit alpha; Complement component 3 receptor 3 subunit; Complement Component Receptor 3 Alpha; Complement receptor type 3, alpha subunit; CR 3 alpha chain (CR3A); CR 3 alpha chain; CR-3 alpha chain; CR3; CR3A; F730045J24Rik; Integrin Alpha M; Integrin alpha M chain; Integrin alpha-M; Integrin beta 2 alpha subunit; Integrin subunit alpha M; integrin, alpha M (complement component 3 receptor 3 subunit); ITAM_HUMAN; ITGAM; Leukocyte adhesion receptor MO1; Ly-40; MAC 1; Mac-1a; MAC1; Mac1, alpha subunit; MAC1A; Macrophage antigen alpha polypeptide; MGC117044; Mo1, alpha subunit; MO1A; Neutrophil adherence receptor alpha M subunit; Neutrophil adherence receptor; SLEB6;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P11215 ITAM_HUMAN:

Predominantly expressed in monocytes and granulocytes (PubMed:1346576). Expressed in neutrophils (at protein level) (PubMed:21193407).

Sequence:
MALRVLLLTALTLCHGFNLDTENAMTFQENARGFGQSVVQLQGSRVVVGAPQEIVAANQRGSLYQCDYSTGSCEPIRLQVPVEAVNMSLGLSLAATTSPPQLLACGPTVHQTCSENTYVKGLCFLFGSNLRQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQLKKSKTLFSLMQYSEEFRIHFTFKEFQNNPNPRSLVKPITQLLGRTHTATGIRKVVRELFNITNGARKNAFKILVVITDGEKFGDPLGYEDVIPEADREGVIRYVIGVGDAFRSEKSRQELNTIASKPPRDHVFQVNNFEALKTIQNQLREKIFAIEGTQTGSSSSFEHEMSQEGFSAAITSNGPLLSTVGSYDWAGGVFLYTSKEKSTFINMTRVDSDMNDAYLGYAAAIILRNRVQSLVLGAPRYQHIGLVAMFRQNTGMWESNANVKGTQIGAYFGASLCSVDVDSNGSTDLVLIGAPHYYEQTRGGQVSVCPLPRGRARWQCDAVLYGEQGQPWGRFGAALTVLGDVNGDKLTDVAIGAPGEEDNRGAVYLFHGTSGSGISPSHSQRIAGSKLSPRLQYFGQSLSGGQDLTMDGLVDLTVGAQGHVLLLRSQPVLRVKAIMEFNPREVARNVFECNDQVVKGKEAGEVRVCLHVQKSTRDRLREGQIQSVVTYDLALDSGRPHSRAVFNETKNSTRRQTQVLGLTQTCETLKLQLPNCIEDPVSPIVLRLNFSLVGTPLSAFGNLRPVLAEDAQRLFTALFPFEKNCGNDNICQDDLSITFSFMSLDCLVVGGPREFNVTVTVRNDGEDSYRTQVTFFFPLDLSYRKVSTLQNQRSQRSWRLACESASSTEVSGALKSTSCSINHPIFPENSEVTFNITFDVDSKASLGNKLLLKANVTSENNMPRTNKTEFQLELPVKYAVYMVVTSHGVSTKYLNFTASENTSRVMQHQYQVSNLGQRSLPISLVFLVPVRLNQTVIWDRPQVTFSENLSSTCHTKERLPSHSDFLAELRKAPVVNCSIAVCQRIQCDIPFFGIQEEFNATLKGNLSFDWYIKTSHNHLLIVSTAEILFNDSVFTLLPGQGAFVRSQTETKVEPFEVPNPLPLIVGSSVGGLLLLALITAALYKLGFFKRQYKDMMSEGGPPGAEPQ

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
88
Sheep
88
Dog
88
Rabbit
88
Horse
86
Pig
75
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P11215 As Substrate

Site PTM Type Enzyme
S574 Phosphorylation
S577 Phosphorylation
Y676 Phosphorylation
T805 Phosphorylation
N900 N-Glycosylation
T930 Phosphorylation
S931 Phosphorylation
N940 N-Glycosylation
N946 N-Glycosylation
S1142 Phosphorylation

Research Backgrounds

Function:

Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain. Regulates neutrophil migration. In association with beta subunit ITGB2/CD18, required for CD177-PRTN3-mediated activation of TNF primed neutrophils. May regulate phagocytosis-induced apoptosis in extravasated neutrophils (By similarity). May play a role in mast cell development (By similarity). Required with TYROBP/DAP12 in microglia to control production of microglial superoxide ions which promote the neuronal apoptosis that occurs during brain development (By similarity).

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Membrane raft>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Predominantly expressed in monocytes and granulocytes. Expressed in neutrophils (at protein level).

Subunit Structure:

Heterodimer of an alpha and a beta subunit. ITGAM associates with ITGB2. Found in a complex with CD177 and ITGB2/CD18. Interacts with JAM3. Interacts with THBD. Interacts with complement factor H/CFH; this interaction mediates adhesion of neutrophils to pathogens leading to pathogen clearance.

Family&Domains:

The integrin I-domain (insert) is a VWFA domain. Integrins with I-domains do not undergo protease cleavage.

Belongs to the integrin alpha chain family.

Research Fields

· Cellular Processes > Transport and catabolism > Phagosome.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Staphylococcus aureus infection.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Organismal Systems > Immune system > Complement and coagulation cascades.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

References

1). Liu X et al. Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-κB activation through upregulating sirtuin 7 in dental pulp fibroblasts. CELL PROLIFERATION 2022 Apr 11;e13227. (PubMed: 35411569) [IF=8.5]

Application: IF/ICC    Species: rat    Sample: Dental pulp fibroblasts

FIGURE 5|Therapeutic effect of combined administration of RvE1 and LXA4 in a rat pulpitis model. (A) Representative haematoxylin–eosinstained images on days 1, 3 and 7 after surgery. (B) Representative immunofluorescence images of CD11b on days 1, 3 and 7 after surgery.

2). Ding L et al. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. Frontiers in Immunology 2022 Mar 17;13:831101. (PubMed: 35371079) [IF=7.3]

3). Meihuan Zhao et al. Inhibition of NLRP3 inflammasome activation and pyroptosis with the ethyl acetate fraction of Bungeanum ameliorated cognitive dysfunction in aged mice. Food & Function 2021 Jul 06; (PubMed: 34231604) [IF=6.1]

4). Liu C et al. The Role of Bone Morphogenetic Protein 4 in Microglial Polarization in the Process of Neuropathic Pain. Journal of Inflammation Research 2022 May 3;15:2803-2817. (PubMed: 35535051) [IF=4.5]

5). Sun JJ et al. Infiltration of Blood-Derived Macrophages Contributes to the Development of Diabetic Neuropathy. Journal of Immunology Research 2019 Aug 26;2019:7597382 (PubMed: 31534976) [IF=4.1]

6). Yang et al. Surfactant protein A is expressed in the central nervous system of rats with experimental autoimmune encephalomyelitis, and suppresses inflammation in human astrocytes and microglia. Molecular Medicine Reports 2017 Jun;15(6):3555-3565 (PubMed: 28393255) [IF=3.4]

Application: WB    Species: rat    Sample:

Figure 3. Western blot analysis of GFAP, Iba‑1, CD11b and SP‑A in the rat CNS at different stages of EAE. (A) Proteins obtained from the rat CNS at the initial, peak and recovery stages of EAE were detected for GFAP, IBA‑1, CD11b and SP‑A via western blotting. (B) Quantitative analysis of western blots was performed and levels were normalized relative to β‑actin. Results are presented as the mean ± standard deviation. * P

Application: IHC    Species: rat    Sample:

Figure 2. H&E staining and immunohistochemical staining of GFAP, Iba‑1, CD11b and SP‑A in the rat CNS at different stages of EAE. (A) CNS sections at initial, peak and recovery stages of EAE were stained for inflammation by H&E, GFAP‑positive astrocytes, Iba‑1‑postive microglia, CD11b general marker of inflammatory cells and SP‑A. Whole image magnification, x200 and corner image magnification, x400. Section of rats under normal conditions served as the control. Arrows indicate the location of SP‑A expressing cells. (B) Lu sections of normal rats were stained as a positive control. Negative control sections of normal rat CNS were treated with secondary antibody only and were unstained for GFAP, Iba‑1, CD11b and SP‑A. Magnification, x400. H&E, hematoxylin and eosin; GFAP, glial fibrillary acidic protein; Iba‑1, ionized calcium‑binding adapter molecule 1; SP‑A, surfactant protein‑A; Lu, lung; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis.

7). He G et al. Dexmedetomidine attenuates neuroinflammation and microglia activation in LPS-stimulated BV2 microglia cells through targeting circ-Shank3/miR-140-3p/TLR4 axis. European Journal of Histochemistry 2023 Jul 26;67(3) (PubMed: 37491974) [IF=2.0]

Application: WB    Species: Mouse    Sample: BV2 cells

Figure 5. Dex attenuates LPS-induced microglia activation by modulating circ-Shank3/miR-140-3p axis. BV2 cells were treated with 20 μg/mL Dex plus miR-140-3p mimics, circ-Shank3 siRNA1 or circ-Shank3 siRNA1 + miR-140-3p inhibitor, followed by treatment with 10 μg/mL LPS. A-C) Immunofluorescence assay was used to estimate the expression of Iba-1, CD11b and BDNF in BV2 cells, based on the fluorescence intensity; Iba-1, CD11b or BDNF, red color; DAPI, blue color.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.